Table 5 Baseline characteristics and outcome in non-lateralized group according to contralateral suppression
Non-lateralized group (N = 20) | p-value | ||
|---|---|---|---|
Contralateral suppression (N = 9) | Non-contralateral suppression (N = 11) | ||
Initial DDD | 1.7 (0.5–4.8) | 1.6 (0.0–3.7) | 0.741 |
Post DDD | 0.8 (0.0–2.3) | 1.1 (0.0–4.6) | 0.194 |
Change in DDD % | −34.0 (−100 − + 135) | −16.1 (0.0 − + 230) | 0.046 |
Lateralization index, baseline | 2.1 (1.3–2.6) | 1.9 (1.0–2.4) | 0.823 |
Lateralization index, post ACTH | 2.0 (1.0–2.4) | 1.6 (1.0–2.8) | 0.431 |
Contralateral suppression index* | 0.5 (0.3–0.9) | 2.4 (1.3–5.1) | 0.035 |
PAC (ng/dL) | 44.1 (25.4–227.2) | 36.5 (21.4–119.2) | 0.758 |
Plasma renin activity (ng/dL) | 0.38 (0.10–1.43) | 0.16 (0.10–0.39)) | 0.014 |
ARR | 307.4 (38.4–1192.0) | 404.21 (62.1–1263.1) | 0.933 |
Post-therapeutic SBP (mmHg) | 125.8 (115–148) | 128.2 (107–160) | 0.991 |
Post-therapeutic DBP (mmHg) | 82.4 (70–103) | 89.8 (60–120) | 0.896 |
Post PAC (ng/dL) | 20.0 (5.4–40.5) | 19.0 (5.3–48.6) | 0.654 |
Post Plasma renin activity (ng/ml/h) | 1.4 (0.27–3.50) | 4.51 (0.10–21.25) | 0.076 |
Post ARR | 22.1 (1.6.4) | 40.7 (4.5–131.8) | 0.135 |
Clinical outcomes | |||
Complete clinical success | 3/9 (33.3) | 1/11 (9.1) | 0.001 |
Partial clinical success | 5/9 (55.6) | 7/11 (63.6) | 0.699 |
Absent clinical success | 1/9 (11.1) | 3/11 (27.2) | 0.052 |